Fertility Preservation in People With Cancer: ASCO Guideline Update.

IF 42.1 1区 医学 Q1 ONCOLOGY
Journal of Clinical Oncology Pub Date : 2025-04-20 Epub Date: 2025-03-19 DOI:10.1200/JCO-24-02782
H Irene Su, Christina Lacchetti, Joseph Letourneau, Ann H Partridge, Rubina Qamar, Gwendolyn P Quinn, Joyce Reinecke, James F Smith, Megan Tesch, W Hamish Wallace, Erica T Wang, Alison W Loren
{"title":"Fertility Preservation in People With Cancer: ASCO Guideline Update.","authors":"H Irene Su, Christina Lacchetti, Joseph Letourneau, Ann H Partridge, Rubina Qamar, Gwendolyn P Quinn, Joyce Reinecke, James F Smith, Megan Tesch, W Hamish Wallace, Erica T Wang, Alison W Loren","doi":"10.1200/JCO-24-02782","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To provide updated fertility preservation (FP) recommendations for people with cancer.</p><p><strong>Methods: </strong>A multidisciplinary Expert Panel convened and updated the systematic review.</p><p><strong>Results: </strong>One hundred sixty-six studies comprise the evidence base.</p><p><strong>Recommendations: </strong>People with cancer should be evaluated for and counseled about reproductive risks at diagnosis and during survivorship. Patients interested in or uncertain about FP should be referred to reproductive specialists. FP approaches should be discussed before cancer-directed therapy. Sperm cryopreservation should be offered to males before cancer-directed treatment, with testicular sperm extraction if unable to provide semen samples. Testicular tissue cryopreservation in prepubertal males is experimental and should be offered only in a clinical trial. Males should be advised of potentially higher genetic damage risks in sperm collected soon after cancer-directed therapy initiation and completion. For females, established FP methods should be offered, including embryo, oocyte, and ovarian tissue cryopreservation (OTC), ovarian transposition, and conservative gynecologic surgery. In vitro maturation of oocytes may be offered as an emerging method. Post-treatment FP may be offered to people who did not undergo pretreatment FP or cryopreserve enough oocytes or embryos. Gonadotropin-releasing hormone agonist (GnRHa) should not be used in place of established FP methods but may be offered as an adjunct to females with breast cancer. For patients with oncologic emergencies requiring urgent oncologic therapy, GnRHa may be offered for menstrual suppression. Established FP methods in children who have begun puberty should be offered with patient assent and parent/guardian consent. The only established method for prepubertal females is OTC. Oncology teams should ensure prompt access to a multidisciplinary FP team. Clinicians should advocate for comprehensive FP services coverage and help patients access benefits.Additional information is available at www.asco.org/survivorship-guidelines.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1488-1515"},"PeriodicalIF":42.1000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO-24-02782","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To provide updated fertility preservation (FP) recommendations for people with cancer.

Methods: A multidisciplinary Expert Panel convened and updated the systematic review.

Results: One hundred sixty-six studies comprise the evidence base.

Recommendations: People with cancer should be evaluated for and counseled about reproductive risks at diagnosis and during survivorship. Patients interested in or uncertain about FP should be referred to reproductive specialists. FP approaches should be discussed before cancer-directed therapy. Sperm cryopreservation should be offered to males before cancer-directed treatment, with testicular sperm extraction if unable to provide semen samples. Testicular tissue cryopreservation in prepubertal males is experimental and should be offered only in a clinical trial. Males should be advised of potentially higher genetic damage risks in sperm collected soon after cancer-directed therapy initiation and completion. For females, established FP methods should be offered, including embryo, oocyte, and ovarian tissue cryopreservation (OTC), ovarian transposition, and conservative gynecologic surgery. In vitro maturation of oocytes may be offered as an emerging method. Post-treatment FP may be offered to people who did not undergo pretreatment FP or cryopreserve enough oocytes or embryos. Gonadotropin-releasing hormone agonist (GnRHa) should not be used in place of established FP methods but may be offered as an adjunct to females with breast cancer. For patients with oncologic emergencies requiring urgent oncologic therapy, GnRHa may be offered for menstrual suppression. Established FP methods in children who have begun puberty should be offered with patient assent and parent/guardian consent. The only established method for prepubertal females is OTC. Oncology teams should ensure prompt access to a multidisciplinary FP team. Clinicians should advocate for comprehensive FP services coverage and help patients access benefits.Additional information is available at www.asco.org/survivorship-guidelines.

保留癌症患者的生育能力:ASCO指南更新。
目的:为癌症患者提供最新的生育能力保存(FP)建议。方法:多学科专家小组召集并更新系统评价。结果:166项研究构成了证据基础。建议:癌症患者应在诊断和生存期间接受生殖风险评估和咨询。对计划生育感兴趣或不确定的患者应咨询生殖专家。在癌症定向治疗之前应该讨论FP方法。在针对癌症的治疗之前,应向男性提供精子冷冻保存,如果无法提供精液样本,则应提取睾丸精子。睾丸组织冷冻保存在青春期前的男性是实验性的,应该只在临床试验中提供。应告知男性,在癌症定向治疗开始和完成后不久收集的精子可能存在较高的遗传损伤风险。对于女性,应提供成熟的计划生育方法,包括胚胎、卵母细胞和卵巢组织冷冻保存(OTC)、卵巢转位和保守妇科手术。卵母细胞体外成熟可能是一种新兴的方法。治疗后的计划生育可以提供给那些没有接受预处理计划生育或冷冻保存足够的卵母细胞或胚胎的人。促性腺激素释放激素激动剂(GnRHa)不应取代既定的计划生育方法,但可以作为乳腺癌女性患者的辅助手段。对于需要紧急肿瘤治疗的肿瘤急症患者,GnRHa可用于抑制月经。在已进入青春期的儿童中,应在患者同意和家长/监护人同意的情况下提供既定的计划生育方法。对于青春期前的女性,唯一确定的方法是OTC。肿瘤团队应确保及时获得多学科计划生育团队的帮助。临床医生应倡导全面的计划生育服务覆盖范围,并帮助患者获得福利。更多信息请访问www.asco.org/survivorship-guidelines。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Clinical Oncology
Journal of Clinical Oncology 医学-肿瘤学
CiteScore
41.20
自引率
2.20%
发文量
8215
审稿时长
2 months
期刊介绍: The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信